about
Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE studyDyslipidaemia, hypercoagulability and the metabolic syndromeFenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a reviewUnusual manifestation of diarrhea-associated haemolytic uraemic syndrome in an adult.Triglycerides and vascular risk: insights from epidemiological data and interventional studies.Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentThe effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT studyElevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?Statins and solid organ transplantation.Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels.Fish oils and vascular disease prevention: an update.Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?Implementation of guidelines for the management of arterial hypertension. The impulsion studyEndothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management.Myocardial perfusion scintigraphy in asymptomatic diabetic patients: a critical review.Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes?Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.Should raising high-density lipoprotein cholesterol be a matter of debate?Role of antihypertensive drugs in arterial 'de-stiffening' and central pulsatile hemodynamics.11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?Hyperuricaemia: more than just a cause of gout?Colesevelam: a new and improved bile acid sequestrant?Effect of quinapril or metoprolol on circadian sympathetic and parasympathetic modulation after acute myocardial infarction.Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study.The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study.Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study.Targeting vascular risk in patients with metabolic syndrome but without diabetes.Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.To switch (statins) or not to switch? That is the question.Blood pressure levels constitute the most important determinant of the metabolic syndrome in a Mediterranean population: a discrimination analysis.Statin-fibrate combination for mixed dyslipidaemia: a limited option?Lipid-lowering agents and new onset diabetes mellitus.Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population.Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome.Acute kidney injury: Short-term statin therapy for prevention of contrast-induced AKI.The DEFINE study: a bright future for CETP inhibitors?Alcohol consumption and the heart.Statin-fibrate combinations in patients with combined hyperlipedemia.Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease.
P50
Q28174014-3CBD8D61-6875-4846-8E9A-C2CEA18CF2B7Q28199524-51F1E513-2990-43C0-95E0-769780BDDBC0Q28220294-574F2D0F-E59B-49A8-A550-3FDEF6E6A809Q33379008-9C99F673-B7F5-4BD1-8F9B-05E12B243BF8Q33428275-B3FE8DAE-5237-4164-B7DB-4F36E7069582Q35029623-953A9E4D-220B-4FA8-AB57-B7A714712B78Q35587723-3C011172-C8F7-469A-8C77-0B5D7BD4B12CQ35674320-FBD0E777-0E95-4AB0-B2B9-4556111CB372Q36595636-F9B02A31-335D-4284-BFE2-0B1AC7992BFDQ36683681-0938BE2D-2124-4634-B983-8901D1EAC5C8Q36755797-63D6724A-E88F-4491-AC27-AAC14D082AE0Q36990244-C1575E36-08CB-416C-8659-A41319B45CF3Q37138777-67644466-50D0-4C73-A3A0-45090CEE067DQ37239716-850F0DB5-B977-488F-A923-CDD8DCE28F9EQ37615690-B77ADC08-C5A3-4864-B0E7-4903F5FF02DFQ37768122-0285BCE6-2963-4DBC-BF61-C084047624A2Q37815518-CF331B96-85F0-4A1B-A81B-77660B668E25Q37825946-A74BE9C9-44C8-4598-AF84-3CB930F72343Q37988402-A8EBB1AD-8440-4E2C-AEFE-7DA48F54B980Q38006018-29A65CB1-DC31-445C-9E22-28593B6593FEQ38015005-B34422C2-6577-4A94-A647-697BEBC0EEC3Q38049115-6347D989-16B9-41EA-9DF6-2A5607499C23Q38073880-01A5EDAF-9997-4436-9FAF-BCFC02B6C396Q39522907-C7CE2828-C490-42A1-B3B2-050EC0BC52E3Q39702444-5A1F1E62-6926-4A14-B8A5-54DAD7712EA3Q39720393-DEC92B88-49FC-4C93-BAFE-5D8F9B9E28A2Q42171889-FBAE4AB7-3CE3-4B92-B06C-202C08D53D21Q42664674-AD96885B-BB2F-4DF9-8B8D-B0753DE3BE5EQ42791977-A330259D-8421-409A-B7DA-367641EC152AQ42854439-289E6814-6486-42B0-BBA3-222C44B365EAQ42935106-E7D1ECD9-AD18-47DA-BB07-394256E8A274Q42956447-A4D12E31-53C2-4E49-BAA9-84BC4FE29996Q43058605-3B886ACB-BE7C-479E-A0B5-8576F73BA0ACQ43193058-BA93B053-8938-4D56-87AB-B33AD2485F5AQ43207802-BDAAB280-A797-4CF3-AD3C-8E3ED80F7DABQ43427326-1BD2D93A-26EB-4C3F-B9E6-24BC86AEB2C2Q43439911-FB3F7043-795A-4915-ABE6-8456C3A4BC1FQ43494950-3475C520-C7D1-48F6-8579-8BA72BEBDECAQ43568570-FA37239A-AF0A-4AC7-A0EC-50922EF3EF35Q43687650-B323E2C3-7BFF-4593-85B0-D0596B76D9D2
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Vasilios G Athyros
@nl
Vasilios G Athyros
@sl
Vasilios G. Athyros
@en
Vasilios G. Athyros
@es
type
label
Vasilios G Athyros
@nl
Vasilios G Athyros
@sl
Vasilios G. Athyros
@en
Vasilios G. Athyros
@es
prefLabel
Vasilios G Athyros
@nl
Vasilios G Athyros
@sl
Vasilios G. Athyros
@en
Vasilios G. Athyros
@es
P106
P1153
7005230222
P21
P2798
P31
P496
0000-0002-0882-8676